anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a preparation method for an ivermectin solution used for fowls, so as to make the ivermectin solution mix with water easily and be administered by drinking water, to guarantee accuracy of dosage and to prevent side effects brought by unevenly mixed materials. The preparation method comprises the steps of taking 10-20 L of 95% ethanol and, dissolving 0.5-5 kg of ivermectin in a water bath at a temperature of 70 DEG C, adding 2-10 L of Tween-80 after the ivermectin is dissolved, stirring uniformly, adding dimethylformamide to a total volume of 100 L, keeping for 15-20 min after uniformly stirring, thus obtaining the ivermectin solution used for the fowls after the solution is clarified. The 95% ethanol is used as a solvent and the ivermectin is dissolved in a water bath, so that the added Tween-80 has an emulsification effect and then is mixed with dimethylformamide. The obtained solution has an effect of mixing with water in any proportion. The ivermectin solution is administrated by drinking water, so that accuracy of dosage can be guaranteed; and the ivermectin solution is convenient for use and reduces labor force consumption. Besides, side effects brought by unevenly mixed materials can be prevented.
Cardiomyocyte hypertrophy is a major outcome of pathological cardiac hypertrophy. The m6A demethylase ALKBH5 is reported to be associated with cardiovascular diseases, whereas the functional role of ALKBH5 in cardiomyocyte hypertrophy remains confused. We engineered Alkbh5 siRNA (siAlkbh5) and Alkbh5 overexpressing plasmid (Alkbh5 OE) to transfect cardiomyocytes. Subsequently, RNA immunoprecipitation (RIP)-qPCR, MeRIP-qPCR analysis and the dual-luciferase reporter assays were applied to elucidate the regulatory mechanism of ALKBH5 on cardiomyocyte hypertrophy. Our study identified ALKBH5 as a new contributor of cardiomyocyte hypertrophy. ALKBH5 showed upregulation in both phenylephrine (PE)-induced cardiomyocyte hypertrophic responses in vitro and transverse aortic constriction (TAC)/high fat diet (HFD)-induced pathological cardiac hypertrophy in vivo. Knockdown or overexpression of ALKBH5 regulated the occurrence of hypertrophic responses, including the increased cardiomyocyte surface areas and elevation of the hypertrophic marker levels, such as brain natriuretic peptide (BNP) and atrial natriuretic peptide (ANP). Mechanically, we indicated that ALKBH5 activated JAK2/STAT3 signaling pathway and mediated m6A demethylation on Stat3 mRNA, but not Jak2 mRNA, resulting in the phosphorylation and nuclear translocation of STAT3, which enhances the transcription of hypertrophic genes (e.g., Nppa) and ultimately leads to the emergence of cardiomyocytes hypertrophic growth. Our work highlights the functional role of ALKBH5 in regulating the onset of cardiomyocyte hypertrophy and provides a potential target for hypertrophic heart diseases prevention and treatment. ALKBH5 activated JAK2/STAT3 signaling pathway and mediated m6A demethylation on Stat3 mRNA, but not Jak2 mRNA, resulting in the phosphorylation and nuclear translocation of STAT3, which enhances the transcription of hypertrophic genes (e.g., Nppa) and ultimately leads to the emergence of cardiomyocytes hypertrophic growth.
Yoga is a form of exercise with a focus on the structural alignment of the physical body. As Yoga movements involve a complex motion of core muscles and lower limb muscles, this exercise may be beneficial for gait stability. Gait performance is a sensitive indicator of overall health and functional status, and gait impairment can lead to a high risk of falling or diminished mobility. It was hypothesized that yoga instructors may have a more symmetric gait pattern and better balance ability than healthy non-yoga controls. Impact of yoga training on gait symmetry and single leg stance balance will be investigated. Twenty five yoga instructors and twenty five age/sex-matched healthy subjects will be recruited to conduct walking and static stability tests and these subjects' gait data and body movements will be measured during the experiments by attaching inertial measurement units (IMUs) to their lower limbs and trunks. Calculation of the subjects' asymmetry of swing phases during their gait cycles will be done to evaluate the gait performance. Afterwards, subjects will conduct four different one-leg stance tests. Two balance indexes will be defined and the recorded IMU data will be applied to evaluate the subjects' balance ability. Four performance indexes will then be defined to assess gait performance and single leg stance stability to quantify the potential advantages of yoga practice.
A sedentary lifestyle has been deemed deleterious to health. It contributes to many chronic diseases and illnesses as well as an increase in all-cause mortality. The objective of this study is to investigate if electronic prompted interruptions in sitting time can reduce sedentary behavior at work as well as have an effect on job satisfaction, and musculoskeletal complaints. The participants will be randomly assigned to one of two groups, intervention (n=31) and control (n=31). Informed consent, demographic and socioeconomic data will be obtained from each participant. A questionnaire that includes three different scales will be administered before and after the 12-week intervention to all participants: Occupational Sitting and Physical Activity Questionnaire, Job Satisfaction Index, and Nordic Musculoskeletal Symptoms. Also, physical data will be measured: BMI, percent body fat and waist circumference. All participants will be provided with the Amazfit BIP device to track steps during work hours. The intervention group will receive a prompt every hour during their workday via an iOS application, Stand-Up, through the Amazfit BIP device. The prompt is to interrupt sitting time and encourage two-minutes of physical activity. The intervention group will receive examples of physical activity in addition to educational material on the health benefits of increasing physical activity in the workplace via verbal instruction and written materials. Data analysis will be conducted to determine if there is a difference in sitting time between the two groups over time using repeated-measures ANOVA. Independent samples t-tests will be used to compare job satisfaction and the physical biomarkers for obesity among the intervention and control groups. Chi-square will be used to analyze the reported musculoskeletal complaints between the two groups. If necessary, all analyses will be controlled for age, gender, race/ethnicity, and socioeconomic status.
The present invention provides a stable-type Cucurbitacin medicinal liquid compositions, which comprises: Cucurbitacin, liquid-state fat, and vitamin E, wherein the weight ratio between Cucurbitacin and the liquid-state fat is 1:100 ~ 1:5000, and the weight of vitamin E is 1% ~ 50% of that of the liquid-state fat. The liquid-state fat is the fat which is in the liquid state at room temperature, which can be selected from MCT (Medium-Chain Triglyceride), LCT (Long-Chain Triglyceride), STG (structured-triglycerides), soybean oil, peanut oil, olive oil, or coconut oil, or the mixture of two or more than two of them. The liquid-state fats such as MCT, etc. can dissolve Cucurbitacin well to enhance the anti-tumor effect of Cucurbitacin, and to reduce the individual difference. Vitamin E can increase the stability of Cucurbitacin. The molecular-state stable-type Cucurbitacin liquid compositions of the present invention can be further made into soft capsule and liquid-type hard capsule, and can be used for oral administration or external use. By adding emulsifier to make it into emulsion, the present invention can be applied by injection, oral administration or external use.
On Day 1 of treatment period 1, Serelaxin will be administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen The routine exercise assessment will commence at minute 120. In treatment period 2, on day 15 ± 1-day washout, matching placebo will be administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen.
A mechanism is provided in a data processing system comprising a processor and a memory, the memory comprising instructions that are executed by the processor to specifically configure the processor to implement a medical imaging story board creation engine. The medical imaging story board creation engine executing in the data processing system receives a patient data structure comprising a medical imaging study comprising a plurality of electronic medical images. The medical imaging story board creation engine analyzes the patient data structure to determine a modality of the medical imaging study. The medical imaging story board creation engine determines, based on the determined modality of the medical imaging study, for each electronic image in the medical imaging study, at least one of an image mode or viewpoint. The medical imaging story board creation engine performs a saliency feature extraction operation on the electronic medical images in the medical imaging study based on the image mode or viewpoint of each of the electronic medical images. The medical imaging story board creation engine selects a subset of electronic medical images based on results of the saliency feature extraction. The medical imaging story board creation engine generates and outputs a collection of selected electronic medical images based on the selection of the subset of electronic medical images to form a medical imaging story board.
This is an epidemiological (the study of health-related states or events in specific populations) study of patients with mild to moderate Alzheimer's who have been treated previously with anticholinesterase drugs (class of drugs that act in the central nervous system) up to a maximum of fifteen days. The data for each patient will be recorded on two occasions; first at a baseline visit and then at a follow-up visit at 3 months. At the baseline visit, after the patient or his/her legal representative has given written informed consent, each participating neurologist will use the study questionnaire to collect patient sociodemographic characteristics (characteristics such as age, years of education, race, sex, religion, birthplace, income, occupation, geographic location, among others), medical history and diagnosis of Alzheimer's disease. The neurologist will also record treatment for Alzheimer's disease and concomitant hypnotic medications (simultaneous use of medications that induce sleep) and evaluate the patient using two scales: the Pittsburgh Sleep Quality Index (PSQI) to record sleep disturbances and the Epworth Sleepiness Scale to determine the level of daytime sleepiness. Alzheimer treatment and concomitant hypnotic medications will be recorded again at the follow-up visit. Patient sleep quality using the PSQI and daytime sleepiness using the Epworth scale will also be evaluated again at this visit.
Participants will be randomized to receive a standard weight-based regimen of artemether-lumefantrine (Coartem®, Novartis Pharmaceuticals Corporation, Missouri, USA). Children in the AL arm received two daily doses (morning and evening) orally, over 3 days (6 doses total at 0, 8, 24, 36, 48, and 60 hours post initial dose, administered with food or milk at the clinic and at home). To promote and evaluate adherence, study staff called parents in the evening to remind them to give the AL dose to the child and to bring the blister pack to the clinic the next day for confirmation.
A stable but reversible phenotype switch from normal to persister state is advantageous to the intracellular pathogens to cause recurrent infections and to evade the host immune system. Staphylococcus aureus is a versatile opportunistic pathogen known to cause chronic infections with significant mortality. One of the notable features is the ability to switch to a per-sisters cell, which is found in planktonic and biofilm states. This phenotypic switch is always an open question to explore the hidden fundamental science that coheres with a calculated or fortuitous move. Toxin-antitoxin modules, nutrient stress, and an erroneous translation-enabled state of dormancy entail this persistent behaviour in S. aureus. It is paramount to get a clear picture of why the cell chooses to enter a persistent condition, as it would decide the course of treatment. Analyzing the exit from a persistent state to an active state and the subsequent repercussion of this transition is essential to determine its role in chronic infections. This review attempts to provide a constructed argument discussing the most widely accepted mechanisms and identifying the various attributes of persistence.
PURPOSE: Prior investigations regarding the effect of obesity on inguinal hernia repair have been mixed. The aim of our study was to retrospectively compare perioperative outcomes, recurrence rate, and quality of life between obese and non-obese patients undergoing inguinal hernia repair.
METHODS: Patients who underwent inguinal hernia repair by any approach at a single institution were identified from a prospectively maintained quality database. Patients with a body mass index (BMI) greater than or equal to 30 kg/m2 were considered obese. Quality of life was measured with the Surgical Outcomes Measurement System (SOMS) and Carolinas Comfort Scale (CSS) surveys. Differences between obese and non-obese patients were assessed using independent samples t-tests, Wilcoxon rank-sum, and chi-square tests.
RESULTS: Between 2010 and 2021, a total of 5575 patients underwent inguinal hernia repair. Fifteen percent of patients were identified as obese (835 patients, mean BMI 33.2 ± 3.3 kg/m2). A significantly higher percentage of obese patients were diabetic, and operative time and estimated blood loss were higher in the obese group (all p < 0.001). Rates of hernia recurrence in obese patients was significantly more likely than in non-obese patients (4.2% vs 2.0%, p < 0.001). Up to 2 years postoperatively, a greater percentage of obese patients reported worse quality of life on the SOMS and more bothersome symptoms on the CCS.
CONCLUSIONS: Inguinal hernia repair in obese patients is a more technically challenging operation. Long-term follow-up revealed a greater risk of hernia recurrence and worse quality of life up to 2 years postoperatively in this patient population.
ABSTRACT  Arylcarbonylaminoalkyl-dihydro-oxo-pyridines of Formula I       are disclosed wherein aryl is an aromatic or heteroaromatic system, n is zero through 5; R and R(1), are hydrogen, or loweralkyl; W is hydrogen, (hetero)-(aryl)-loweralkyl; Z is hydrogen, CH2OR(2), CHO, (CO)OR(2), (CO)NR(2)z.  Processes for the preparation of compound I are also disclosed.  Compounds I are suitable for the treatment of disorders of the cardiovascular system, for example of hypertension, of cardiac insufficiency or of disturbances of blood flow in the coronary systems such as, for example, angina. Disturbances of cerebral and peripheral blood flow are likewise influenced beneficially.  Furthermore, compounds I are able to influence smooth-muscle organs such as uterus, bronchi, intestines and biliary system, the urinary tract (ureter, bladder and urethra) in the sense of spasmolysis.  They are therefore also suitable for the treatment of diseases associated with spasms of these organs, for example for the treatment of premature labor in pregnancy, of ureteral or biliary colic, of obstructive airway diseases such as asthma, of disturbances of intestinal motility such as, for example, of irritable colon or of bladder incontinence. Additionally, compounds of formula I can serve as anti-convulsants in the treatment of epilepsy and as hair growth inducers in the treatment of baldness.
Patients will receive daily oral pazopanib on days 1-21 in a 21-day cycle. This will be combined with intravenous or oral irinotecan and oral temozolomide on days 1-5. Dosing of irinotecan will be from 25 to 37.5 mg/m2/day for IV dosing or from 45 to 67.5 mg/m2/dose for oral dosing and oral temozolomide will be 100 mg/m2/day for dose levels at each assigned dose level. In the absence of disease progression or unacceptable toxicity, patients will receive cycles of therapy repeating every 21 days for a maximum of 12 months on study.
The present invention provides a preparation of a ternary composite microsphere and a preparation method thereof. The main components of the preparation comprise model medicine, calcium alginate, chitosan and a copolymer of glycolide and lactide. The preparation method comprises: a calcium alginate microcapsule with small particle diameter through the emulsification of W/O and the washing of isopropyl alcohol; the calcium alginate microcapsule is further wrapped by the chitosan so as to form an alginic acid-chitosan double-layer microcapsule with a compact structure; then the alginic acid-chitosan double-layer microcapsule is wrapped into the copolymer of glycolide and lactide by an emulsification-solvent volatilization method so as to form a three-layer composite microsphere. The composite microsphere provided by the present invention favorably protects protein medicine and polypeptide medicine in the environment of the hydrophilic sodium alginate-chitosan microcapsule, obviously reduces the phenomenon of sudden release and reduces incomplete release so as to achieve long time release of medicine. The composite microsphere can regulate the release mode of medicine through changing the components of PLGA. The formulation of the ternary composite microsphere preparation of the present invention comprises injection formulation and oral formulation.
BACKGROUND: Activation of the IL-33/ST2 axis leads to the production of proinflammatory cytokines and thus to the triggering of osteoclastogenesis, which is why it plays an important role in the immunopathogenesis of periodontitis. The aim of this study was to compare IL-33 levels in serum, plasma, saliva and gingival crevicular fluid (GCF) of subjects with chronic periodontitis (CP) in comparison with the control group (CG).
METHODS: This systematic review and meta-analysis followed the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) and was registered in the Open Science Framework (OSF): https://doi.org/10.17605/OSF.IO/YHUWA . Six electronic databases were used for study identification; PubMed, Google Scholar, ScienceDirect, Web of Science, Scopus and Dentistry & Oral Sciences Source from March 10, 2012 to April 30, 2024. The Joanna Briggs Institute (JBI) tool was used to assess the quality of the included cross-sectional articles and clinical trials.
RESULTS: Of the 949 articles identified, 14 were included according to the inclusion and exclusion criteria. The total number of individuals studied in the included investigations was 814 of whom 445 had CP and 369 were healthy. The reported age range was from 20 to 50 years, with a mean age ± standard deviation of 40.29 ± 7.83 years. Four hundred and twenty-six (52%) patients were men and 388 (48%) were women. Meta-analysis revealed that there is an increase in IL-33 levels in plasma, saliva and GCF of subjects with CP compared to CG (p = * < 0.05).
CONCLUSIONS: This study found a significant increase in IL-33 levels in different biological samples (plasma, saliva and GCF) of individuals with CP compared to CG, thus IL-33 has potential to be a biomarker in the diagnosis of periodontitis.
INTRODUCTION: Despite potential links between diabetes and sensorineural hearing loss (SNHL), routine hearing assessments for diabetic patients are not standard practice. Our study aimed to investigate the prevalence of SNHL and its association with diabetes-related factors among patients with type 2 diabetes mellitus (T2DM).
RESEARCH DESIGN AND METHODS: This cross-sectional study was conducted at the Diabetes Clinic, Jinnah Postgraduate Medical Centre, Karachi, Pakistan, from May to September 2021. A total of 396 patients fulfilling the inclusion criteria participated after informed consent. Data collection involved a sociodemographic profile, Michigan Neuropathy Screening Instrument examination followed by pure-tone audiometry and laboratory tests including haemoglobin A1C (HbA1c). HL was defined using better ear four-frequency pure-tone average of ≥26 dB HL and graded as per WHO criteria. Statistical analyses were performed using SPSS. χ2, independent t-test and multinomial logistic regression analyses were applied. P<0.05 at 95% CI was considered significant.
RESULTS: Our study revealed a high prevalence of SNHL among patients with T2DM. Mild HL was seen in 55.8%, while 18.7% suffered from moderate HL. Common audiological symptoms included difficulty understanding speech in noisy surroundings (44.2%), balance problems (42.9%), sentence repetition (35.9%), tinnitus (32.3%) and differentiating consonants (31.1%). Hearing impairment predominantly affected low (0.25-0.5 kHz) and high (4-8 kHz) frequencies with a significant difference at 4 kHz among both sexes (t (394)=2.8, p=0.004). Peripheral neuropathy was significantly associated with SNHL on multinomial logistic regression after adjusting with age, sex, body mass index and the presence of any comorbidities. Diabetes duration, HbA1c or family history of diabetes was found unrelated to SNHL severity.
CONCLUSIONS: The study highlights the substantial prevalence of SNHL among patients with T2DM and emphasises the importance of targeted audiological care as part of a holistic approach to diabetes management. Addressing HL early may significantly improve communication and overall quality of life.
In 2016, France passed a major law that is unique in giving terminally ill and suffering patients the right to the controversial procedure of continuous deep sedation until death (CDS). In so doing, the law identifies CDS as a sui generis clinical practice, distinct from other forms of palliative sedation therapy, as well as from euthanasia. As such, it reconfigures the ethical debate over CDS in interesting ways. This paper addresses one aspect of this reconfiguration and its implications for the intentions at work in this complex time at the end of life. The concept of intention is often considered central to the ethics of end-of-life care, but its role is recognized to be problematic, with charges of elusiveness and ambiguity. I aim to show that consideration of the French law affords a new understanding of the intentionality of CDS, and that in addition to the obvious importance of this for clarifying the ethics of the practice, it may suggest new ways of addressing the wider problem of ambiguous clinical intentions at end of life.